Clinical Trial

Singaporean scientists are reprogramming immune cells with magnetic fields, eradicating tumors in preclinical trials and offering hope for a future without chemo.

As pharma giants dominate the obesity space with GLP-1 drugs, Corbus Pharmaceuticals is betting on a different mechanism. Will its upcoming data rewrite the rules?

XORTX starts manufacturing its gout drug XORLO™, a pivotal move toward FDA approval. But can it navigate a competitive market and its own financial hurdles?

PhenoNet completes a key trial milestone for its ALS therapy, not with a new molecule, but with a repurposed drug and a savvy regulatory and operational plan.

Encoded Therapeutics' ETX101 shows potential to not only halt seizures but also reverse developmental delays, suggesting a paradigm shift for rare neurological disorders.

New AI-powered analysis of Endeavor BioMedicines' taladegib shows significant lung volume gains, offering a glimmer of hope for reversing damage in IPF.

A deep dive into PRF Technologies' audacious dual-engine strategy, as it simultaneously pushes for FDA trials and commercializes AI for the green energy grid.

Tangram Therapeutics signals a major strategic push, advancing its novel MASH drug into patient trials while hiring a veteran CDO to steer its pipeline.

Adicet Bio nears a pivotal data readout for its lupus CAR-T, now viable for outpatient use, while launching a novel solid tumor attack in prostate cancer.

As it launches a pivotal trial for its MYC inhibitor, Persevere Therapeutics adds a seasoned CEO to its board, signaling a sharp focus on funding and strategy.

XYRA's new trial uses data from wearables to personalize doses of Budiodarone, a safer alternative to today's standard AF drugs. Is this the future?

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

A German biotech's novel drug just won a key FDA designation, a strategic move that could redefine the limits of liver surgery and cancer treatment.

A new blood test can predict preterm birth risk months in advance, shifting prenatal care from reactive crisis to proactive strategy and saving billions.

A small biophysics firm unveils promising data for its at-home headset using magnetic fields to treat Long COVID, heralding a potential shift from pharma to biophysics.

A proposed SXSW panel on longevity medicine forces a crucial question: Are we on the verge of restoring youth, or just drowning in promises? We look at the science.

A new study shows AliveCor's KardiaMobile 6L device nearly doubles arrhythmia detection, signaling a major shift from clinics to patient-led home care.

A $1M award for a novel drug targeting mitochondrial dysfunction is more than just funding; it's a bet on a new paradigm for fighting neurodegeneration.

With positive Phase 1 results, AC Immune's NLRP3 inhibitor not only targets neuro-inflammation but also bolsters the company's independent strategy.